This week in drug discovery (17-21 January) 

News round-up by DDW’s Megan Thomas for 17-21 January, 2022 

When it comes to drug discovery and development, it’s all about the research, the breakthroughs and the next step. DDW’s Megan Thomas has rounded up five stories which highlight this theme of progress. 

1. BenevolentAI announces collaboration with AstraZeneca 

BenevolentAI, a clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca, doubling the number of disease areas being explored through the partnership.   

2. Success for AstraZeneca lung cancer therapy 

AstraZeneca’s Tagrisso (osimertinib) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations. 

3. AlzeCure gets late-breaking neuroscience abstract accepted 

AlzeCure Pharma, a pharmaceutical company that develops small molecule candidate drugs for diseases affecting the central nervous system, has announced that an abstract on clinical data of its candidate drug ACD856 has been accepted for a poster presentation at AD/PD 2022, which this year will be held in Barcelona on March 15-20. 

4. Avacta takes step to increase the tolerability of chemotherapies 

Avacta has added the next pre|CISION drug candidate to its portfolio. AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023. 

5. Evotec and Lilly enter into drug discovery collaboration in metabolic diseases 

Evotec has entered into a drug discovery collaboration with Eli Lilly and Company (Lilly) in the field of metabolic diseases with a focus on kidney diseases and diabetes. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free